Oncolytics Biotech Inc.

Dr. Matt Coffey, our President and CEO, says of our poster at ESMO 2017: This poster outlines a doubling of overall survival in HR+(ER+/PR+)/HER2- patients and p=0.003, as well as the largest safety database available for an oncolytic virus that demonstrates REOLYSIN is safe and well tolerated when administered in combination with chemotherapy. Read more about safety and efficacy data from our ESMO presentations in our press release here: https://goo.gl/1s75nS

We are proud to announce a successful End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for REOLYSIN in combination with paclitaxel, for the treatment of hormone receptor positive, HER2 receptor negative (HR+/HER2-) metastatic breast cancer (mBC) patients. Dr. Matt Coffey, President and CEO of Oncolytics Biotech, says, With statistically significant and clinically compelling overall survival data, Fast Track designation and now clear guidance from the F...DA, we are focused on finalizing the adaptive study design that will include approximately four hundred patients with a pre-determined interim analysis. Importantly, the FDA provided guidance that if the study achieves its primary endpoint, then it will be the only study required for BLA approval. The design of the study and this FDA guidance will also continue to drive our partnering process. Read more in our press release: http://www.oncolyticsbiotech.com//oncolytics-biotech-anno/ See more

Today we announced that the first patient has been treated in the Phase 1b trial MUK eleven, studying REOLYSIN in combination with Celgene Corporation's immunomodulatory drugs (IMiDs), Revlimid or Imnovid as a rescue treatment in relapsing myeloma patients. Dr. Matt Coffey, our President and CEO, says, This is an important trial for Oncolytics as it’s the first to discretely examine the innate immunity component of REOLYSIN’s mechanism of action. Read more about the trial in our press release here: https://goo.gl/TBBg4S

Dr. Matt Coffey, our President and CEO, says of our poster at ESMO 2017: This poster outlines a doubling of overall survival in HR+(ER+/PR+)/HER2- patients and p=0.003, as well as the largest safety database available for an oncolytic virus that demonstrates REOLYSIN is safe and well tolerated when administered in combination with chemotherapy. Read more about safety and efficacy data from our ESMO presentations in our press release here: https://goo.gl/1s75nS

Live today: Chief Medical Officer Andres A. Gutierrez discusses the promise of viral immuno-oncology therapies in Drug Discovery News. Click to learn more http://bit.ly/2eZR3oG

Oncolytics Biotech President and CEO Dr. Matt Coffey featured on The Wall Street Analyzer #interview http://wallstreetanalyzer.com//oncolytics-biotech-inc-tsx/